Korsana Biosciences, Inc. (KRSA)
32.83
-2.16
(-6.17%)
USD |
NASDAQ |
Sep 21, 16:00
33.09
+0.26
(+0.79%)
After-Hours: 20:00
Korsana Biosciences Enterprise Value : 19.88M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 19.88M |
| September 17, 2026 | 19.11M |
| September 16, 2026 | 17.60M |
| September 15, 2026 | 18.11M |
| September 14, 2026 | 17.83M |
| September 11, 2026 | 18.01M |
| September 10, 2026 | 13.54M |
| September 09, 2026 | 14.54M |
| September 08, 2026 | 12.91M |
| September 04, 2026 | 16.70M |
| September 03, 2026 | 19.72M |
| September 02, 2026 | 17.85M |
| September 01, 2026 | 16.36M |
| August 31, 2026 | 14.27M |
| August 28, 2026 | 14.74M |
| August 27, 2026 | 15.59M |
| August 26, 2026 | 16.27M |
| August 25, 2026 | 15.63M |
| August 24, 2026 | 15.34M |
| August 21, 2026 | 15.16M |
| August 20, 2026 | 15.93M |
| August 19, 2026 | 16.19M |
| August 18, 2026 | 16.14M |
| August 17, 2026 | 15.76M |
| August 14, 2026 | 14.74M |
| Date | Value |
|---|---|
| August 13, 2026 | 15.25M |
| August 12, 2026 | 15.29M |
| August 11, 2026 | 13.80M |
| August 10, 2026 | 13.85M |
| August 07, 2026 | 13.80M |
| August 06, 2026 | 13.76M |
| August 05, 2026 | 13.72M |
| August 04, 2026 | 13.55M |
| August 03, 2026 | 13.46M |
| July 31, 2026 | 13.25M |
| July 30, 2026 | 13.50M |
| July 29, 2026 | 13.50M |
| July 28, 2026 | 13.50M |
| July 27, 2026 | 13.50M |
| July 24, 2026 | 13.50M |
| July 23, 2026 | 14.02M |
| July 22, 2026 | 14.06M |
| July 21, 2026 | 14.33M |
| July 20, 2026 | 14.14M |
| July 17, 2026 | 14.10M |
| July 16, 2026 | 14.19M |
| July 15, 2026 | 14.40M |
| July 14, 2026 | 14.91M |
| July 13, 2026 | 14.87M |
| July 10, 2026 | 14.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Climb Bio, Inc. | 625.17M |
| Q32 Bio, Inc. | 149.21M |
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.755M |
| Total Expenses (Quarterly) | 1.755M |
| EPS Diluted (Quarterly) | -2.890 |
| Earnings Yield | -35.82% |
| Normalized Earnings Yield | -35.82 |